TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06660498

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pomalidomide 2 mg
Description: Participants will receive pomalidomide 2 mg/d concurrently with aspirin 75 mg for three cycles, each consisting of 21 days on and a minimum of 7 days off.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo concurrently with aspirin 75 mg for three cycles, each consisting of 21 days on and a minimum of 7 days off.
Study: NCT05125016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Administered once by IV infusion as prophylaxis prior to REGN4336 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Administered once by IV infusion as prophylaxis prior to REGN4336 IV
Study: NCT05732428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARV-471
Description: ARV-471 will be administered orally once daily with food (eg, a light meal of approximately 400 to 600 calories which includes a mixture of fat carbohydrates, and protein) at RP3D for monotherapy defined in study ARV-471-mBC-101, in continuous dosing over 28-day cycles
Study: NCT05600426

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine
Description: cyclosporine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine
Description: cyclosporine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Matched Unrelated Donor Hematopoetic Stem Cell Transplant
Description: Matched Unrelated Donor (MUD) Hematopoietic Stem Cell Transplantation (HSCT)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: horse anti-thymocyte globulin (ATG)
Description: horse anti-thymocyte globulin (ATG)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rabbit anti-thymocyte globulin (ATG)
Description: rabbit anti-thymocyte globulin (ATG)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: methotrexate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: fludarabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: cyclophosphamide

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: low-dose total body irradiation (TBI)
Description: low-dose total body irradiation (TBI)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immunosuppressive Therapy (IST)
Description: Immunosuppressive Therapy (IST)
Study: NCT05143138

Intervention type: DEVICE
Intervention: GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis
Description: Patients treated with the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis as a Bridging Stent

Intervention type: DEVICE
Intervention: GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis
Description: Patients treated with the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis as a Bridging Stent

Intervention type: DEVICE
Intervention: GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis
Description: Patients treated with the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis as a Bridging Stent
Study: NCT06042049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirsevimab
Description: Participants in the first year of life will receive the 1st dose of nirsevimab as a single, fixed intramuscular (IM) dose of 50 mg if body weight is \<5 kg or 100 mg if body weight is ≥5 kg. A 2nd fixed IM dose of 50 mg if body weight is \<5 kg or 100 mg if body weight is ≥5 kg will be administered 5 to 6 months following the 1st dose.
Study: NCT06069843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Ketamine
Description: 0.5 mg/kg IV Ketamine
Study: NCT04922333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risedronate
Description: 150mg over-encapsulated risedronate
Study: NCT06660498

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin 75 mg
Description: Auxiliary Medicinal Product

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 75 mg
Description: Auxiliary Medicinal Product
Study: NCT00256035

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Measuring IL-4 levels

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Measuring IL-4 levels

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Measuring IL-4 levels

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Measuring IL-4 levels
Study: NCT06661447

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tridimensional Onlay autologous bone graft
Description: A thick block from the ramus area of the mandible are cut longitudinally with a microsaw into two thin pieces with the same surface area. The two thin block are used to rebuild the two wall of the future alveolar crest and stabilized with osteosynthesis screw of the edentulous area. The remaining space is filled with a mixture of autogenic and xenogeneic particulate bone.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tridimensional Onlay xenogeneic bone graft
Description: A tridimensional Onlay xenogeneic bone graft is positioned and stabilized with osteosynthesis screw of the edentulous area. The remaining space is filled with a mixture of autogenic and xenogeneic particulate bone.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tridimensional Onlay allogenic bone graft
Description: A tridimensional Onlay allogenic bone graft is positioned and stabilized with osteosynthesis screw of the edentulous area. The remaining space is filled with a mixture of autogenic and xenogeneic particulate bone.
Study: NCT04435639

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual lymph drainage.
Description: Manual Lymphatic drainage:~Patients will receive manual lymphatic drainage by massage for 40 minutes for 5 treatments over a 15 day period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual lymph drainage.
Description: Manual Lymphatic drainage:~Patients will receive manual lymphatic drainage by massage for 40 minutes for 5 treatments over a 15 day period.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coban compression bandage..
Description: Coban compression bandaging: Patients will be wrapped in Coban compression bandaging which stays on until the next treatment. Patients will wear standard compression sleeves during the six month maintenance phase.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adjustable Compression Sleeve
Description: Patients wear an adjustable compression sleeve (Juzo varocare adjustable compression system) between treatments. They will be shown how to put it on and how to tighten the sleeve when needed. Patients will also wear the adjustable compression sleeve in alternation with a standard compression sleeve over a six month maintenance phase.
Study: NCT06626321

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-visit patient text messaging
Description: Patients will be sent text message reminders 3 days and 24 hours prior to their scheduled primary care visit. The messages will inform the patient that a flu shot has been reserved for them at their upcoming visit and encourage the patient to ask their provider about receiving the vaccine.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-visit patient text messaging
Description: Patients will be sent text message reminders 3 days and 24 hours prior to their scheduled primary care visit. The messages will inform the patient that a flu shot has been reserved for them at their upcoming visit and encourage the patient to ask their provider about receiving the vaccine.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Default pended order
Description: A default pended order for the flu vaccine will be pended to the patients upcoming primary care encounter and will be visible to the provider during the visit encounter. Clinical staff will have the option of signing the order or dismissing it if they deem it inappropriate for a given patient.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Default pended order
Description: A default pended order for the flu vaccine will be pended to the patients upcoming primary care encounter and will be visible to the provider during the visit encounter. Clinical staff will have the option of signing the order or dismissing it if they deem it inappropriate for a given patient.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monthly peer comparison feedback
Description: Each month, clinicians will be sent an email containing what percent of their eligible patients received the flu vaccine and how that compares to other peer clinicians in the intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monthly peer comparison feedback
Description: Each month, clinicians will be sent an email containing what percent of their eligible patients received the flu vaccine and how that compares to other peer clinicians in the intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High risk bidirectional pre-visit text messaging
Description: High risk patients randomized to receive the high risk intensification nudge will receive a bidirectional text messaging component prior to their visit. This intervention will query the patient about common questions or concerns about receiving the flu vaccine. If the patient responds, it will provide additional educational materials based on the patient's specific concern(s).
Study: NCT04884035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-220
Description: CC-220 by mouth at the assigned dose starting on Day 1 for 14 consecutive days of the 21-day treatment cycle for 6 cycles of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-220
Description: CC-220 by mouth at the assigned dose starting on Day 1 for 14 consecutive days of the 21-day treatment cycle for 6 cycles of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 on Day 1 by intravenous (IV) infusion or 1400 mg (SC) subcutaneous (from Cycle 2) of a 21-day treatment cycle for up to a total of 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 on Day 1 by intravenous (IV) infusion or 1400 mg (SC) subcutaneous (from Cycle 2) of a 21-day treatment cycle for up to a total of 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 750mg/m2 on Day 1 by IV infusion of a 21-day treatment cycle for up to a total of 6 cycles
Study: NCT06327815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xigduo (Dapagliflozin and Metformin hydrochloride extended-release) tablets
Description: 10 mg Dapagliflozin/1000 mg Metformin HCl extended-release

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin tablets and Metformin HCl extended-release tablets
Description: Dapagliflozin tablets: 10 mg Metformin HCl extended-release tablets: 1000 mg
Study: NCT04922333

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules containing placebo tablets
Study: NCT05935527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: POLAT-001
Description: Subjects will be randomized to receive three injections per under eyebag, either 1 mg/mL or 2 mg/mL and 120 microliter volume, at each of three treatment visits.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be randomized to receive three injections of 120 microliters total of Normal Saline per under eyebag at each of three treatment visits.
Study: NCT05378464

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cell (DC1) Vaccine
Description: Participants will receive a DC1 vaccine injection at 1.0-2.0 x 10\^7 cells, either to groin lymph notes or to tumor if accessible once a week for 3 weeks on days 1, 8 and 15. Participants will receive DC1 vaccine boosters every 3 weeks x 3.
Study: NCT06428916

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tucking position during endotracheal suctioning
Description: , the staff nurse will perform the endotracheal suctioning while the researcher will carried out the intervention
Study: NCT06227676

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cramp Bites by Aunt Flo's Kitchen
Description: Participants who are randomly assigned this snack are instructed to eat one serving each day, starting 2 days before their next onset of menstruation, and extending 3 days into their menstrual cycle. They are instructed to eat their assigned snack each time they experience menstrual cramps, whether spasmodic or congestive.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cramp Bites by Aunt Flo's Kitchen
Description: Participants who are randomly assigned this snack are instructed to eat one serving each day, starting 2 days before their next onset of menstruation, and extending 3 days into their menstrual cycle. They are instructed to eat their assigned snack each time they experience menstrual cramps, whether spasmodic or congestive.
Study: NCT05261256

Intervention type: DIAGNOSTIC_TEST
Intervention: Exercise stress echocardiography
Description: Study participants perform an exercise stress echocardiography on a semi-supine bicycle ergometer using using a continuous incremental bicycle protocol with a work rate increment every 3 minutes according to gender and weight.

Intervention type: DIAGNOSTIC_TEST
Intervention: Exercise stress echocardiography
Description: Study participants perform an exercise stress echocardiography on a semi-supine bicycle ergometer using using a continuous incremental bicycle protocol with a work rate increment every 3 minutes according to gender and weight.
Study: NCT06311968

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton radiotherapy
Description: Patients who received R0 resection will receive 45GyE per 18 fractions proton irradiation. Patients who received R1 resection will receive 50GyE per 20 fractions proton irradiation. Patients with thymus cancer should receive combined platinum based chemotherapy (including etoposide combined with cisplatin / carboplatin / loplatin / nedaplatin, paclitaxel combined with cisplatin / carboplatin / loplatin / nedaplatin, Docetaxel combined with cisplatin / carboplatin / loplatin / nedaplatin) for at least 4 cycles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: combined platinum based chemotherapy
Description: combined platinum based chemotherapy
Study: NCT05660551

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Demostration
Description: This group will be demonstrated on a model after the theoretical training. The maneuvers used in the management of shoulder dystocia will be shown to the students on the model, respectively.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telesimulation
Description: After the theoretical training for this group, telesimulation will be applied. A scenario will be created for the telesimulation experience and a video will be shot with this scenario. These videos will be watched by the students in groups of 4 on Microsoft Teams and a case discussion will be made through this scenario.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kahoot Game
Description: Kahoot, a game-based program, will be applied to this group one week after the theoretical training. The game will be organized according to the learning objectives and achievements related to shoulder dystocia.
Study: NCT04541550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMP-001 Low Dose
Description: AMP-001, is manufactured from the amniotic membrane of the placenta and does not contain living cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMP-001 Medium Dose
Description: AMP-001, is manufactured from the amniotic membrane of the placenta and does not contain living cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMP-001 High Dose
Description: AMP-001, is manufactured from the amniotic membrane of the placenta and does not contain living cells.
Study: NCT04779853

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood samples for pertussis antibody testing
Description: Blood samples will be sent to the laboratories of the National Centers of Expertise within 24-48 hours of blood collection. The samples will be transferred to the reference laboratory of SPCSEEM in Almaty, Kazakhstan. Serum samples will be stored in the reference laboratory at a temperature of -20 C.
Study: NCT05088421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BWC0977
Description: SAD Cohorts: Double-blind dosing will occur. Six participants will receive single doses of BWC0977. The dose escalation steps may be altered following review of the safety data upon completion of each cohort.~MAD Cohorts: Double blind dosing will occur. Six participants in each cohort will receive multiple doses of BWC0977. The dose escalation steps may be altered following review of the safety data upon completion of each cohort. Dosing will commence on the morning of Day 1. Dosing frequency to be confirmed based on safety, tolerability and PK data from SAD cohorts. Daily dosing will continue for a total of 10 consecutive days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SAD Cohorts: Two participants in each cohort will receive matching placebo. MAD Cohorts: Two participants in each cohort will receive matching placebo.
Study: NCT04659499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel in combination with pyrotinib
Description: Nab-paclitaxel I.V. 260mg/m2 every 3 weeks for 12 weeks plus pyrotinib oral 240mg daily for one year
Study: NCT06094166

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Quantitative imaging MR parameters

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Quantitative imaging MR parameters
Study: NCT04566172

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Description: Participants will receive an inspiratory muscle training that they will do leading up to the day of their surgery.
Study: NCT06342700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilzabrutinib crystalline form
Description: Pharmaceutical form:Film coated tablet Route of administration:Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilzabrutinib crystalline form
Description: Pharmaceutical form:Film coated tablet Route of administration:Oral
Study: NCT06342700

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rilzabrutinib amorphous form
Description: Pharmaceutical form:Film coated tablet Route of administration:Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rilzabrutinib amorphous form
Description: Pharmaceutical form:Film coated tablet Route of administration:Oral
Study: NCT05917015

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Treatment
Description: Participants will receive daily 2 tablets of Proglucamune for a duration of 6 weeks. Each tablet contains \~100 mg ß-glucan derived from Baker's Yeast extract (Saccharomyces cerevisiae, cell wall), Reishi mushroom powder (Ganoderma lucidum), and Shitake mushroom powder (Lentinula edodes).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive daily 2 placebo tablets containing microcrystalline cellulose. The size, shape and appearance of the placebo tablet is identical to the treatment tablet.
Study: NCT06473961

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Tumor Infiltrating Lymphocytes
Description: A tumor sample is resected from each participant and cultured ex vivo to generate tumor infiltrating lymphocytes. After lymphodepletion, patients are infused GC101 TIL followed low-dose PD-1 antibody.
Study: NCT05917067

Intervention type: DIAGNOSTIC_TEST
Intervention: Fluorescence imaging of the parathyroid glands of children
Description: Patients that participate in this study will always receive standard care. For the purpose of this study, the camera settings (i.e. camera distance to the operating field, switching of OR-lights, and angle of the camera on the operating field) and ICG-protocol (i.e. dose, injection speed) will be standardized among the participating centers in order to generate an homogeneous data set for quantification of the fluorescence signal intensity.
Study: NCT05401487

Intervention type: OTHER
Intervention: Pre-hospital and hospital care
Description: Pre-hospital care not exceeding 60 min and a whole body CT scan within 45 min for patients categorized as unstable or critical by the pre-hospital doctor and 90 minutes for patients deemed potentially serious.
Study: NCT05323474

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual rehabilitation
Description: Usual rehabilitation according to the practice of the Haute Autorité de Santé (HAS)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation optimized
Description: Rehabilitation optimized according to the study protocol
Study: NCT06537999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNTH103
Description: * Day 1: IV loading dose~* Week 1 to Week 15: DNTH103 administered SC every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNTH103
Description: * Day 1: IV loading dose~* Week 1 to Week 15: DNTH103 administered SC every 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Day 1: IV infusion of placebo~* Week 1 to Week 15: placebo administered SC every 2 weeks
Study: NCT05774002

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aims to Decrease Anxiety and Pain Treatment (ADAPT)
Description: One pre-operative and 4 post-operative sessions of cognitive behavioral therapy (CBT) treatment in the first two months, beginning 2-3 weeks after surgery, will be completed.
Study: NCT04936230

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo urine and blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo urine and blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan